ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > FDA filing

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Nov 25, 2022 5:37pm

270 Views

Post# 35129217

FDA filing

Soon the filing for PMN310 will be released and phase 1a will start. This will show toxicity and we know by the primate study that it will be negligible. This step will take us to 1B where all the excitement resides. I laugh at those that say to sell because why would they care, the answer is they can't buy back in. Tough luck.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market